Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma.
2/5 보강
TL;DR
This review details synthetic hypericin’s evolution and its unique non-mutagenic, light-activated mechanism, and establishes its efficacy and safety in patch- and plaque-stage mycosis fungoides, comparing it to other SDTs.
OpenAlex 토픽 ·
Cutaneous lymphoproliferative disorders research
Photodynamic Therapy Research Studies
Nonmelanoma Skin Cancer Studies
This review details synthetic hypericin’s evolution and its unique non-mutagenic, light-activated mechanism, and establishes its efficacy and safety in patch- and plaque-stage mycosis fungoides, compa
APA
James R. Poligone, Priyanka Kadam, et al. (2026). Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma.. Expert opinion on investigational drugs, 35(4), 257-263. https://doi.org/10.1080/13543784.2026.2643305
MLA
James R. Poligone, et al.. "Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma.." Expert opinion on investigational drugs, vol. 35, no. 4, 2026, pp. 257-263.
PMID
41843408 ↗
Abstract 한글 요약
[INTRODUCTION] Effective skin-directed therapies (SDT) are the cornerstone for managing early-stage Cutaneous T-cell Lymphoma (CTCL). However, standard treatments like PUVA phototherapy and topical mechlorethamine carry significant drawbacks, including mutagenic risk and treatment-limiting skin reactions. This unmet need has driven demand for safer options. Topical photodynamic therapy with synthetic hypericin (research name: SGX301; trade name: HyBryte™) has emerged as a novel agent addressing this gap.
[AREAS COVERED] This review details synthetic hypericin's evolution and its unique non-mutagenic, light-activated mechanism. It generates singlet oxygen, preferentially inducing apoptosis in malignant T-cells. We analyze key clinical trials, including the pivotal Phase III FLASH study, to establish its efficacy and safety in patch- and plaque-stage mycosis fungoides, comparing it to other SDTs.
[EXPERT OPINION] Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients.
[AREAS COVERED] This review details synthetic hypericin's evolution and its unique non-mutagenic, light-activated mechanism. It generates singlet oxygen, preferentially inducing apoptosis in malignant T-cells. We analyze key clinical trials, including the pivotal Phase III FLASH study, to establish its efficacy and safety in patch- and plaque-stage mycosis fungoides, comparing it to other SDTs.
[EXPERT OPINION] Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.